<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Excretion of pyridinoline and <z:chebi fb="1" ids="15841">polypeptide</z:chebi>-bound <z:chebi fb="2" ids="18095">hydroxyproline</z:chebi> with urine was studied in 27 children with hereditary impairment of connective tissue </plain></SENT>
<SENT sid="1" pm="."><plain>At the same time, effects of beta-adrenoblocking agents and vitamin complex, prescribed during preoperation period before thoracoplasty in hereditary chest deformation, were investigated </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical efficiency of the treatment depended distinctly on the initial value of ratios pyridinoline/<z:chebi fb="0" ids="16737">creatinine</z:chebi> and <z:chebi fb="1" ids="15841">polypeptide</z:chebi>-bound <z:chebi fb="2" ids="18095">hydroxyproline</z:chebi>/<z:chebi fb="0" ids="16737">creatinine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Total positive effect of the therapeutic course, considering also echocardiographic examination and postoperational complications, was observed in 44% of patients with Ehlers-Dunlop syndrome and in 75% of patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
</text></document>